CN108024962A - 用于治疗癌症的雷帕霉素和雷帕霉素衍生物的稳定的脂质体制剂 - Google Patents

用于治疗癌症的雷帕霉素和雷帕霉素衍生物的稳定的脂质体制剂 Download PDF

Info

Publication number
CN108024962A
CN108024962A CN201580082921.XA CN201580082921A CN108024962A CN 108024962 A CN108024962 A CN 108024962A CN 201580082921 A CN201580082921 A CN 201580082921A CN 108024962 A CN108024962 A CN 108024962A
Authority
CN
China
Prior art keywords
liposome
stabilization
liposomal formulation
liposomes
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580082921.XA
Other languages
English (en)
Chinese (zh)
Inventor
游廷彬
施志伟
苏矢宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Manli International Ltd Singapore
Original Assignee
Manli International Ltd Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manli International Ltd Singapore filed Critical Manli International Ltd Singapore
Publication of CN108024962A publication Critical patent/CN108024962A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580082921.XA 2015-09-09 2015-09-21 用于治疗癌症的雷帕霉素和雷帕霉素衍生物的稳定的脂质体制剂 Pending CN108024962A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/849,100 2015-09-09
US14/849,100 US20170065520A1 (en) 2015-09-09 2015-09-09 Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer
PCT/US2015/051206 WO2017044135A1 (en) 2015-09-09 2015-09-21 Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer

Publications (1)

Publication Number Publication Date
CN108024962A true CN108024962A (zh) 2018-05-11

Family

ID=58189920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580082921.XA Pending CN108024962A (zh) 2015-09-09 2015-09-21 用于治疗癌症的雷帕霉素和雷帕霉素衍生物的稳定的脂质体制剂

Country Status (6)

Country Link
US (1) US20170065520A1 (enExample)
EP (1) EP3346989B1 (enExample)
JP (1) JP2018527335A (enExample)
CN (1) CN108024962A (enExample)
ES (1) ES2849730T3 (enExample)
WO (1) WO2017044135A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115843250A (zh) * 2020-04-06 2023-03-24 迭戈·多尔切塔 向中枢神经系统中施用mTOR抑制剂
CN117159724A (zh) * 2023-04-04 2023-12-05 上海交通大学医学院附属仁济医院 一种脂质体-dna水凝胶复合给药系统及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140328898A1 (en) * 2013-03-15 2014-11-06 Children's National Medical Center Nano-Liposomal Formulations and Methods of Use
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
IT201900003887A1 (it) 2019-03-18 2020-09-18 Fidia Farm Spa Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione
US12433874B2 (en) 2022-04-28 2025-10-07 Prescience Biotechnology Inc. Liposome comprising rapamycin or a derivative thereof and use thereof in therapy
WO2025037276A1 (en) * 2023-08-16 2025-02-20 Jina Pharmaceuticals Inc. COMPOSITIONS CONTAINING mTOR INHIBITORS AND LIPIDS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559121A (en) * 1993-09-30 1996-09-24 American Home Products Corporation Rapamycin formulations for oral administration
US6110491A (en) * 1996-10-22 2000-08-29 Hermes Biosciences, Inc. Compound-loaded liposomes and methods for their preparation
CN103501766A (zh) * 2011-03-01 2014-01-08 to-BBB控股股份有限公司 不良水溶性物质的高主动脂质体装载
CN103845290A (zh) * 2012-12-03 2014-06-11 曼丽国际有限公司 Umirolimus及其衍生物用于治疗癌症的用途
WO2014121211A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes
US20150079155A1 (en) * 2012-03-14 2015-03-19 Bioneer A/S Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004389A (es) * 2007-10-23 2010-05-20 Transave Inc Formulaciones de vancomicina liposomales.
US20110244028A1 (en) * 2008-09-26 2011-10-06 Steve Leigh Method of solubilizing biologically active compounds
WO2013176223A1 (ja) * 2012-05-23 2013-11-28 国立大学法人大阪大学 炎症性疾患治療用医薬組成物
US9801862B2 (en) * 2013-11-05 2017-10-31 Gustavo A. Garcia-Sánchez Immunosuppressive treatments, formulations and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559121A (en) * 1993-09-30 1996-09-24 American Home Products Corporation Rapamycin formulations for oral administration
US6110491A (en) * 1996-10-22 2000-08-29 Hermes Biosciences, Inc. Compound-loaded liposomes and methods for their preparation
CN103501766A (zh) * 2011-03-01 2014-01-08 to-BBB控股股份有限公司 不良水溶性物质的高主动脂质体装载
US20150079155A1 (en) * 2012-03-14 2015-03-19 Bioneer A/S Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood
CN103845290A (zh) * 2012-12-03 2014-06-11 曼丽国际有限公司 Umirolimus及其衍生物用于治疗癌症的用途
WO2014121211A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
潘卫三: "《工业药剂学》", 31 August 2015, 中国医药科技出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115843250A (zh) * 2020-04-06 2023-03-24 迭戈·多尔切塔 向中枢神经系统中施用mTOR抑制剂
CN117159724A (zh) * 2023-04-04 2023-12-05 上海交通大学医学院附属仁济医院 一种脂质体-dna水凝胶复合给药系统及其制备方法

Also Published As

Publication number Publication date
EP3346989A1 (en) 2018-07-18
WO2017044135A1 (en) 2017-03-16
EP3346989A4 (en) 2019-05-08
US20170065520A1 (en) 2017-03-09
EP3346989B1 (en) 2020-12-30
ES2849730T3 (es) 2021-08-20
JP2018527335A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
US11446247B2 (en) Liposome composition and pharmaceutical composition
CN108024962A (zh) 用于治疗癌症的雷帕霉素和雷帕霉素衍生物的稳定的脂质体制剂
CN108366965B (zh) 稳定喜树碱药物组合物
TWI362931B (en) Irinotecan formulation
CN103153285B (zh) 脂质体组合物及其制造方法
CN109922808B (zh) 用于治疗癌症的脂质体制剂
CN101991538B (zh) 一种含tpgs的脂质体组合物及其应用
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
EP4601621A1 (en) Liposome compositions for delivery of compounds and methods thereof
WO2004017943A2 (en) Non-vesicular cationic lipid formulations
US20100166843A1 (en) Pharmaceutical composition comprising a campothecin derivative
HK40070304A (en) Stabilizing camptothecin pharmaceutical compositions
HK40045737A (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
HK40009643A (en) Liposomal formulation for use in the treatment of cancer
HK40009643B (en) Liposomal formulation for use in the treatment of cancer
HK1258407B (en) Stabilizing camptothecin pharmaceutical compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180511